Mazen Sobh Vice President , Commercial Development at Cognetivity
FIVE MINUTES WITH ...
Mazen Sobh Vice President , Commercial Development at Cognetivity
Working to transform cognitive testing to help millions around the world , the Cogentivity team has developed a solution that spots early signs of cognitive impairments in individuals . With deep sector experience in neuroscience , artificial intelligence ( AI ), medicine and neurology , AI Magazine speaks to Mazen Sobh Vice President for Commercial Development at Cognetivity to learn how the company is delivering a new paradigm in global healthcare .
Q . Can you tell me about your company and your role ?
» Cognetivity Neurosciences is a company that was established in the UK and is a spinoff from Cambridge University . From the university , two scientists PhD students collaborated and developed an application that specialises in identifying early or subtle signs of cognitive impairments in individuals . This application , CognICA , which can be used on an iPad or smartphone , combines cutting-edge neuroscience with artificial intelligence . The technology which has been patented and also peer-reviewed , displays 100 images in quick succession , asking patients to simply identify whether they see an animal in each or not . Due to the ‘ fear or food ’ response , humans react strongly to animal imagery , activating large areas of their brain . AI analysis compares their reactions to how others in their age group responded and this generates a result that indicates how healthy a patient ' s brain is when compared to “ We have big plans for expansion ”
22 February 2022